|34.57||-0.5000||-1.43%||Vol 398.03K||1Y Perf 44.56%|
|Apr 13th, 2021 15:41 DELAYED|
|- -%||- -|
|Target Price||108.10||Analyst Rating||Strong Buy 1.00|
|Potential %||213.61||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||849.49M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||26.05||Earnings Date||11th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th May 2021|
|Estimated EPS Next Report||-0.89|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||357.11K|
|Avg. Monthly Volume||587.23K|
|Avg. Quarterly Volume||547.57K|
BioXcel Therapeutics Inc. (NASDAQ: BTAI) stock closed at 35.07 per share at the end of the most recent trading day (a -2.23% change compared to the prior day closing price) with a volume of 281.73K shares and market capitalization of 849.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. BioXcel Therapeutics Inc. CEO is Vimal Mehta.
The one-year performance of BioXcel Therapeutics Inc. stock is 44.56%, while year-to-date (YTD) performance is -24.09%. BTAI stock has a five-year performance of %. Its 52-week range is between 21.56 and 71.5, which gives BTAI stock a 52-week price range ratio of 26.05%
BioXcel Therapeutics Inc. currently has a PE ratio of -9.60, a price-to-book (PB) ratio of 4.28, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.31%, a ROC of -53.79% and a ROE of -69.64%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BioXcel Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. BioXcel Therapeutics Inc.’s next earnings report date is 11th May 2021.
The consensus rating of Wall Street analysts for BioXcel Therapeutics Inc. is Strong Buy (1), with a target price of $108.1, which is +213.61% compared to the current price. The earnings rating for BioXcel Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioXcel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioXcel Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.43, ATR14 : 4.60, CCI20 : -110.44, Chaikin Money Flow : -0.24, MACD : -3.00, Money Flow Index : 22.68, ROC : -13.15, RSI : 42.07, STOCH (14,3) : 6.46, STOCH RSI : 0.71, UO : 32.40, Williams %R : -93.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioXcel Therapeutics Inc. in the last 12-months were: Frank Yocca (Option Excercise at a value of $6 150), Frank Yocca (Sold 45 000 shares of value $2 318 540 ), Richard I. Steinhart (Option Excercise at a value of $20 813), Richard I. Steinhart (Sold 3 750 shares of value $180 563 ), Vincent O'Neill (Option Excercise at a value of $126 400), Vincent O'Neill (Sold 50 000 shares of value $2 626 178 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
This could take some time, please wait.